Compare PIM & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIM | EQ |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 157.4M |
| IPO Year | N/A | 2018 |
| Metric | PIM | EQ |
|---|---|---|
| Price | $3.10 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 46.6K | ★ 816.7K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.07 | $0.46 |
| 52 Week High | $3.50 | $3.54 |
| Indicator | PIM | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 37.32 |
| Support Level | $3.07 | $1.68 |
| Resistance Level | $3.33 | $2.61 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 21.43 | 11.53 |
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.